MeSH Review:
Renal Osteodystrophy
González,
Lund,
Martin,
McCartney,
Tondravi,
Sampath,
Hruska,
Antonelli,
Hottel,
Slatopolsky,
Cozzolino,
Lu,
Finch,
Dusso,
Staniforth,
Wein,
Webster,
Coen,
Ballanti,
Balducci,
Calabria,
Fischer,
Jankovic,
Manni,
Morosetti,
Moscaritolo,
Sardella,
Bonucci,
Jehle,
Ostertag,
Schulten,
Schulz,
Jehle,
Stracke,
Fiedler,
Deuber,
Keller,
Boehm,
Baylink,
Mohan,
Goodman,
Jüppner,
Salusky,
Sherrard,
Hörl,
- Long-term effects of small doses of 1,25-dihydroxycholecalciferol in renal osteodystrophy. Ahmed, K.Y., Varghese, Z., Wills, M.R., Meinhard, E.A., Moorhead, J.F. Lancet (1978)
- Vitamin D endocrinology. DeLuca, H.F. Ann. Intern. Med. (1976)
- Bone morphogenetic proteins in development and homeostasis of kidney. Simic, P., Vukicevic, S. Cytokine Growth Factor Rev. (2005)
- Quantitative analysis of crosslinks pyridinoline and pentosidine in articular cartilage of patients with bone and joint disorders. Takahashi, M., Kushida, K., Ohishi, T., Kawana, K., Hoshino, H., Uchiyama, A., Inoue, T. Arthritis Rheum. (1994)
- Bone scintigraphy in renal osteodystrophy. de Graaf, P., Schicht, I.M., Pauwels, E.K., te Velde, J., de Graeff, J. J. Nucl. Med. (1978)
- Recent developments in aluminum toxicology. Monteagudo, F.S., Cassidy, M.J., Folb, P.I. Medical toxicology and adverse drug experience. (1989)
- The prevalence of bone aluminum deposition in renal osteodystrophy and its relation to the response to calcitriol therapy. Ott, S.M., Maloney, N.A., Coburn, J.W., Alfrey, A.C., Sherrard, D.J. N. Engl. J. Med. (1982)
- Increased growth after long-term oral 1alpha,25-vitamin D3 in childhood renal osteodystrophy. Chesney, R.W., Moorthy, A.V., Eisman, J.A., Jax, D.K., Mazess, R.B., DeLuca, H.F. N. Engl. J. Med. (1978)
- Metabolites and analogues of vitamin D. Which for what? Haussler, M.R., Cordy, P.E. JAMA (1982)
- 1-alpha-hydroxyvitamin D3 in chronic renal failure. A potent analogue of the kidney hormone, 1,25-dihydroxycholecalciferol. Chan, J.C., Oldham, S.B., Holick, M.F., DeLuca, H.F. JAMA (1975)
- Phosphate control and 25-hydroxycholecalciferol administration in preventing experimental renal osteodystrophy in the dog. Rutherford, W.E., Bordier, P., Marie, P., Hruska, K., Harter, H., Greenwalt, A., Blondin, J., Haddad, J., Bricker, N., Slatopolsky, E. J. Clin. Invest. (1977)
- Propranolol for renal osteodystrophy. Fournier, A., Coevoet, B., Leroux, J.L., de Fremont, J.F., Lambrey, G. Lancet (1978)
- Disappearance of vascular calcifications during treatment of renal osteodystrophy. Two patients treated with high doses of vitamin D and aluminum hydroxide. Verberckmoes, R., Bouillon, R., Krempien, B. Ann. Intern. Med. (1975)
- 1,25(OH)2D levels in dihydrotachysterol-treated patients: influence on 1,25(OH)2D assays. Taylor, A., Norman, M.E. J. Bone Miner. Res. (1987)
- The efficacy of calcifediol in renal osteodystrophy. Recker, R., Schoenfeld, P., Letteri, J., Slatopolsky, E., Goldsmith, R., Brickman, A. Arch. Intern. Med. (1978)
- The localization of aluminium and other elements in bone tissue of a case of renal osteodystrophy with an associated dialysis encephalopathy syndrome. McClure, J., Smith, P.S. J. Pathol. (1984)
- Growth hormone and calcitriol as modifiers of bone formation in renal osteodystrophy. Salusky, I.B., Goodman, W.G. Kidney Int. (1995)
- Comparison of 1 alpha-hydroxycholecalciferol and 25-hydroxycholecalciferol in the treatment of renal osteodystrophy: greater effect of 25-hydroxycholecalciferol on bone mineralization. Fournier, A., Bordier, P., Gueris, J., Sebert, J.L., Marie, P., Ferrière, C., Bedrossian, J., DeLuca, H.F. Kidney Int. (1979)
- Treatment of a murine model of high-turnover renal osteodystrophy by exogenous BMP-7. González, E.A., Lund, R.J., Martin, K.J., McCartney, J.E., Tondravi, M.M., Sampath, T.K., Hruska, K.A. Kidney Int. (2002)
- Extent of alkaline phosphatase cytochemistry vs. extent of tetracycline fluorescence in the evaluation of histodynamic variables of bone formation. Ballanti, P., Coen, G., Taggi, F., Mazzaferro, S., Perruzza, I., Bonucci, E. Bone (1995)
- Fractures and vertebral bone mineral density in patients with renal osteodystrophy. Piraino, B., Chen, T., Cooperstein, L., Segre, G., Puschett, J. Clin. Nephrol. (1988)
- Efficacy of 19-Nor-1,25-(OH)2D2 in the prevention and treatment of hyperparathyroid bone disease in experimental uremia. Slatopolsky, E., Cozzolino, M., Lu, Y., Finch, J., Dusso, A., Staniforth, M., Wein, Y., Webster, J. Kidney Int. (2003)
- The clinical consequences of secondary hyperparathyroidism: focus on clinical outcomes. Hörl, W.H. Nephrol. Dial. Transplant. (2004)
- Increased bone marrow uptake on Tc-99m DMSA scintigraphy in a patient with renal osteodystrophy. Caglar, M., Naldöken, S. Annals of nuclear medicine. (1993)
- Growth hormone treatment of children with chronic renal insufficiency, end-stage renal disease and following renal transplantation--update 1997. Fine, R.N. Journal of pediatric endocrinology & metabolism : JPEM. (1997)
- Oral manifestations of renal osteodystrophy: case report and review of the literature. Antonelli, J.R., Hottel, T.L. Special care in dentistry : official publication of the American Association of Hospital Dentists, the Academy of Dentistry for the Handicapped, and the American Society for Geriatric Dentistry. (2003)
- Insulin-like growth factor system components in hyperparathyroidism and renal osteodystrophy. Jehle, P.M., Ostertag, A., Schulten, K., Schulz, W., Jehle, D.R., Stracke, S., Fiedler, R., Deuber, H.J., Keller, F., Boehm, B.O., Baylink, D.J., Mohan, S. Kidney Int. (2000)
- Parathyroid hormone (PTH), PTH-derived peptides, and new PTH assays in renal osteodystrophy. Goodman, W.G., Jüppner, H., Salusky, I.B., Sherrard, D.J. Kidney Int. (2003)
- Serum osteoprotegerin and renal osteodystrophy. Coen, G., Ballanti, P., Balducci, A., Calabria, S., Fischer, M.S., Jankovic, L., Manni, M., Morosetti, M., Moscaritolo, E., Sardella, D., Bonucci, E. Nephrol. Dial. Transplant. (2002)
- Insulin-like growth factor 1 and 2 serum concentrations in dialysis patients with secondary hyperparathyroidism and adynamic bone disease. Weinreich, T., Zapf, J., Schmidt-Gayk, H., Ritzel, H., Delling, G., Reichel, H. Clin. Nephrol. (1999)
- Bone resorption and mRNA expression of IL-6 and IL-6 receptor in patients with renal osteodystrophy. Langub, M.C., Koszewski, N.J., Turner, H.V., Monier-Faugere, M.C., Geng, Z., Malluche, H.H. Kidney Int. (1996)
- Calcium metabolism in renal failure. David, D.S. Am. J. Med. (1975)
- "High-dose" calcitriol for control of renal osteodystrophy in children on CAPD. Salusky, I.B., Fine, R.N., Kangarloo, H., Gold, R., Paunier, L., Goodman, W.G., Brill, J.E., Gilli, G., Slatopolsky, E., Coburn, J.W. Kidney Int. (1987)
- Pentavalent technetium-99m-dimercaptosuccinic acid scintigraphy in renal osteodystrophy. Higuchi, T., Hirano, T., Inoue, T., Aoki, J., Ueki, K., Wakamatsu, R., Yano, S., Naruse, T., Endo, K. J. Nucl. Med. (1998)
- A prospective, double-blind study of growth failure in children with chronic renal insufficiency and the effectiveness of treatment with calcitriol versus dihydrotachysterol. The Growth Failure in Children with Renal Diseases Investigators. Chan, J.C., McEnery, P.T., Chinchilli, V.M., Abitbol, C.L., Boineau, F.G., Friedman, A.L., Lum, G.M., Roy, S., Ruley, E.J., Strife, C.F. J. Pediatr. (1994)
- Changes in plasma bone GLA protein during treatment of bone disease. Deftos, L.J., Parthemore, J.G., Price, P.A. Calcif. Tissue Int. (1982)